- Home
- CATO vs SAVA Comparison
CATO vs SAVA Comparison
Compare CATO & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- SAVA
- Stock Information
- Founded
- CATO 1946
- SAVA 1998
- Country
- CATO United States
- SAVA United States
- Employees
- CATO N/A
- SAVA N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- SAVA Health Care
- Exchange
- CATO Nasdaq
- SAVA Nasdaq
- Market Cap
- CATO 59.2M
- SAVA 70.5M
- IPO Year
- CATO N/A
- SAVA N/A
- Fundamental
- Price
- CATO $2.86
- SAVA $2.16
- Analyst Decision
- CATO
- SAVA Buy
- Analyst Count
- CATO 0
- SAVA 2
- Target Price
- CATO N/A
- SAVA $54.50
- AVG Volume (30 Days)
- CATO 32.4K
- SAVA 1.1M
- Earning Date
- CATO 08-21-2025
- SAVA 08-07-2025
- Dividend Yield
- CATO 6.05%
- SAVA N/A
- EPS Growth
- CATO N/A
- SAVA N/A
- EPS
- CATO N/A
- SAVA N/A
- Revenue
- CATO $642,949,000.00
- SAVA N/A
- Revenue This Year
- CATO N/A
- SAVA N/A
- Revenue Next Year
- CATO N/A
- SAVA N/A
- P/E Ratio
- CATO N/A
- SAVA N/A
- Revenue Growth
- CATO N/A
- SAVA N/A
- 52 Week Low
- CATO $2.19
- SAVA $1.15
- 52 Week High
- CATO $6.70
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- CATO 64.69
- SAVA 59.08
- Support Level
- CATO $2.84
- SAVA $2.11
- Resistance Level
- CATO $3.05
- SAVA $2.23
- Average True Range (ATR)
- CATO 0.14
- SAVA 0.11
- MACD
- CATO 0.02
- SAVA 0.03
- Stochastic Oscillator
- CATO 100.00
- SAVA 85.42
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.